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okanbakiner@mynet.comAbstractObjective: To determine plasma fetuin-A levels in hypothyroid patients before and after treatment with L-thyroxine (T4)
and to determine the relation between plasma fetuin-A levels with cardiovascular risk factors.
Design: A prospective, controlled, single-blind study.
Methods: Forty-four treatment-naive female patients diagnosed with hypothyroidism and 39 age- and sex-matched control
subjects were enrolled. Anthropometric measurements, blood pressure, plasma TSH, fetuin-A, free T4, LDL-cholesterol,
triglyceride, C-reactive protein, fibrinogen levels, and brachial artery flow-mediated dilatation were measured. All
measurements were repeated after 3 months in the control group and 3 months after the attainment of euthyroidism with
L-T4 replacement in the hypothyroid group.
Baseline data were compared between the two groups. Posttreatment plasma fetuin-A levels of hypothyroid patients were
compared with baseline levels of both groups. The relationship between plasma fetuin-A, TSH levels, and other
cardiovascular risk factors was evaluated.
Results: Plasma fetuin-A levels werew20% lower in hypothyroid female patients compared with the controls (PZ0.0001).
Fetuin-A levels increased by w20% in hypothyroid patients after achievement of euthyroidism (PZ0.0001) and were no
longer different compared with controls (PZ0.38). There was a negative correlation between plasma TSH and fetuin-A levels
(rZK0.79; PZ0.001). There was no significant correlation between plasma fetuin-A levels and cardiovascular risk factors
within or between groups. The fetuin-A levels were normalized with thyroid hormone treatment.
Conclusion: Plasma fetuin-A levels are reduced in female patients with hypothyroidism, which are restored to normal during
restoration of euthyroidism. There was no relation with cardiovascular risk factors.edEuropean Journal of
Endocrinology
(2014) 170, 411–418IntroductionFetuin-A is a carrier plasma glycoprotein synthesized by
the liver and has many functions (1). Its most famous
function is on mineralization biology. Fetuin-A binds the
calcium and phosphate in the medium to form calcipro-
tein particle (CPP). CPP thus removes the calcium from the
medium. It is internalized mainly by the Kupffer cells of
the liver and macrophages in the splenic marginal zone,
and carries out the calcium clearance (2, 3). Various
studies have demonstrated an association between
reduced plasma fetuin-A levels and increased vascularcalcification and cardiovascular mortality in dialysis
patients, increased risk of peripheral arterial disease, and
coronary artery disease in patients with type 2 diabetes
(4, 5, 6). Studies have therefore defined reduced plasma
fetuin-A levels as a new cardiovascular risk factor and
demonstrated that severity of atherosclerosis increases
with low plasma fetuin-A levels (7, 8). In addition, in
humans, fetuin-A has been suggested to provide an
important link between obesity and insulin resistance
(9, 10). It has been demonstrated to act as an endogenous from Bioscientifica.com at 12/26/2019 07:02:44AM
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170 :3 412ligand of Toll-like receptor 4 which is responsible for free
fatty acid-induced inflammatory signaling in adipose
tissue and insulin resistance (11). It has also been shown
that in adipocytes, fatty acids induce fetuin-A gene and
protein expression. Locally produced fetuin-A can act
as a chemo-attractant for macrophages in adipose tissue,
thus it may be regarded as responsible for lipid-induced
inflammatory conditions (12). Hypothyroidism is
associated with accelerated atherosclerosis and increased
risk of coronary artery disease (13). Dyslipidemia,
hypertension, endothelial dysfunction, hyperhomocystei-
nemia, elevated C-reactive protein (CRP) and plasminogen
activator inhibitor-1 levels, and impaired endothelium-
mediated vasodilatation are well known cardiovascular
risk factors (14, 15, 16, 17, 18, 19). Coronary artery
calcification is another factor increasing the cardio-
vascular risk (20), and coronary artery calcification has
recently been shown to associate with reduced serum
thyroxine (T4) levels (21). Sato et al. (22) have
demonstrated that triiodothyronine (T3) increases matrix
gla protein 3–8 times in vascular smooth muscle at
physiological concentration. As matrix gla protein is a
strong inhibitor of vascular calcification, this suggests
that physiological levels of thyroid hormones may
prevent vascular calcification and thus decrease cardio-
vascular risk. Although the anabolic effect of thyroid
hormones on several proteins in the liver including
fetuin-A has been demonstrated in in vitro experimental
studies (23), it is not known whether clinically evident
thyroid dysfunction is associated with the level of
fetuin-A, which is another systemic calcification inhibitor
involved in vascular calcification.
The objective of this study is to evaluate the impact
of hypothyroidism on serum fetuin-A levels and to
investigate the relationship between fetuin-A levels and
conventional cardiovascular risk factors among women
with hypothyroidism.Subjects and methods
Patient selection
Newly diagnosed patients with hypothyroidism at the
endocrinology outpatient clinic of Baskent University,
Adana, Turkey between January 2012 and October 2012,
were enrolled in the study. As serum fetuin-A levels and
its metabolic effects may exhibit sexual dimorphism, only
female patients were included (24, 25). All participants
were between 18 and 50 years old and had hypothyroidism
secondary to autoimmune thyroiditis with serum thyroid-www.eje-online.orgstimulating hormone (TSH) levels above 10 mIU/l. The
diagnosis of chronic autoimmune thyroiditis was estab-
lished in the presence of elevated levels in at least one of
antithyroglobulin (ATA) and antithyroid peroxidase (anti-
TPO) antibody, and/or observation of ultrasonographic
changes in thyroiditis. Exclusion criteria were: postmeno-
pausal, smoking, or pregnant patients; patients with
history of L-T4 replacement therapy; calcium metabolism
disorders, or receiving any medications with potential
effects on calcium metabolism including loop diuretics
or thiazides; and patients with concomitant metabolic
diseases, coronary artery disease, or other disorders that
might alter protein or calcium metabolism including
chronic renal failure, liver failure, malnutrition, or
malignancy. An age-sex-matched healthy group of volun-
teers were included as controls. This studywas approved by
Baskent University institutional review board and ethics
committee (Project no: KA 12/277). The written informed
consent from all participants was obtained at inclusion.
Patients who failed to attend the follow-up visits
regularly or attain target TSH levels (0.45–4.12 mIU/l) with
L-T4 therapy (26), received any medications with potential
effects on calcium metabolism during the follow-up, or
became pregnant were removed from the study.Method
This is a prospective, controlled, single-blind study.
Anthropometric measurements were carried out and BMI
was calculated in all participants. The average of three
consecutive resting arterial blood pressure measurements
was recorded. Venous blood samples were obtained from
the forearm to measure plasma TSH, free T4 (fT4),
LDL-cholesterol, HDL-cholesterol, triglyceride, high-
sensitivity CRP (hs-CRP), and fibrinogen levels after an
overnight fasting. The blood samples obtained for fetuin-A
measurement were stored atK80 8C. Flow-mediated dilata-
tion (FMD) measurement was carried out at the brachial
artery for each participant. These measurements and
analyses were repeated in female patients with hypo-
thyroidism following the treatment (at 3 months of the
attainment of target plasma TSH levels with L-T4 replace-
ment therapy). Similarly, the measurements were repeated
in the control group after 3 months from the baseline.
Baseline data were compared between the two groups.
Baseline data were also compared with the posttreatment
data in the patient group. Posttreatment data of the patient
group was compared with controls. The relationship
between plasma fetuin-A levels and plasma TSH levels and
other cardiovascular risk factors was evaluated.Downloaded from Bioscientifica.com at 12/26/2019 07:02:44AM
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Serum TSH levels were measured with the chemi-
luminescence method using the Abbott-Architect
analyzer, and ATA and anti-TPO levels were measured
with the electrochemiluminescence immunoassay method
using the Modular E170 analyzer (Roche Diagnostic).
Serum fibrinogen was measured with the Clauss
coagulation method using the BCT auto-analyzer
(Siemens Healthcare Diagnostics, Newark, DE, USA).
Serum total cholesterol, HDL-cholesterol, and triglyceride
levels were measured with the original kits of Roche
Modular auto-analyzer (Roche Diagnostic GmbH).
LDL-cholesterol level was calculated with the Friedewald
formula (27).
hs-CRP level wasmeasuredwith the particle-enhanced
immunonephelometric method using the BN II System
(Siemens Healthcare Diagnostics, Marburg, Germany).
Plasma fetuin-A level was measured with the human
fetuin-A ELISA kit provided by Biovendor Laboratory
Medicine (Brno, Czech Republic). The minimum assay
sensitivity of human fetuin-A ELISA kit was 0.35 ng/ml,
and the inter/intra-measurement variability coefficient
was determined as!6.5%.
FMD was measured ultrasonographically at a room
with standard heat-light features at 22–25 8C. All measure-
ments were carried out at supine position, maintaining the
probe parallel to the long axis of the right brachial artery at
2–5 cm above the antecubital fossa, and brachial artery
diameters were obtained at the first time during resting. The
measurement was standardized to measure the diameter
between the vessel wall closest to the probe and the
imaginary line between media and adventitia of the wall
far from the lumen. All measurements were carried out
at B-mode gray scale. The sphygmomanometer on the
forearm was expanded (ca. 250 mmHg pressure) immedi-
ately afterwards, the pressure was maintained for 5 min,
and the measurements were repeated (at approximately
the same place) one min after the reduction of pressure
on the sphygmomanometer. FMD was calculated by the
FMDZvariance in arterial diameter/basal arterial diameter
(%) formula. The Antares US system (Siemens, Inc.,
Mountain, View, CA, USA), multifrequency (4–9 MHz)
linear probe was used in this performance.Statistical analysis
The Social Package for Statistical Sciences (SPSS) version
18.0 was used in the statistical analyses of the data.
Categorical data were summarized as number andpercentages, and numerical data were summarized as
mean and S.D. (median and minimum–maximum when
necessary). Kolmogorov–Smirnov test was used to test
whether numerical data conformed to normal distri-
bution. Intergroup comparison of numerical data was
carried out with independent groups T-test when the
assumptions were met, and with the Mann–Whitney
U test when assumptions were not met. In the comparison
of before–after-dependent numerical measurements,
dependent groups T-test was used in dependent groups
meeting the assumptions, and with the Wilcoxon Signed-
rank test was used when assumptions were not met. The
correlation between fetuin-A and FMD was analyzed with
the Pearson correlation coefficient. A P value of 0.05 was
used to determine statistical significance in all tests.Results
Forty-four female patients with hypothyroidism meeting
the study inclusion criteria were included in the patient
group. Thirty-nine healthy volunteers were included in
the control group. Five patients in the hypothyroidism
group were removed from the study due to failure in
reaching target plasma TSH values in follow-up and
attending control visits, and four subjects in the control
group were removed for failure in obtaining control data
at 3 months. As a result, the study population consisted of
39 female patients and 35 controls.
Baseline data of both groups and their statistical
comparisons are presented in Table 1.
Plasma fetuin-A levels were significantly lower in
female patients with hypothyroidism compared with the
controls at baseline (PZ0.0001). A significant negative
correlation was determined between plasma TSH and
plasma fetuin-A levels in all subjects at baseline (PZ0.001,
rZK0.79). This negative correlation persisted in
hypothyroid patients as well (PZ0.01, rZK0.61). Positive
correlation was found between serum fT4 and plasma
fetuin-A levels in patients at inclusion (PZ0.021, rZ0.49).
None of the baseline cardiovascular risk factors exhibited
correlation with plasma fetuin-A levels in the patient
group (Table 2). Final median serum TSH level was 2.2
(0.5–4.1) mIU/l and was lower than baseline values
(PZ0.0001) in the patient group at the end of the study
period. Mean L-T4 dose given to normalize TSH was
calculated as 1.49G0.71 mg/kg per day per patient. Final
serum TSH levels of the patient group were statistically
indifferent to that of the control group (PZ0.17). Baseline
and 3-month serum TSH levels of the control group were
not different either (PZ0.36). Median plasma fetuin-Awww.eje-online.org
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Table 1 Baseline characteristics and statistical comparisons of the two groups.
Patient (nZ39) Control (nZ35)
PMedian (Min–Max) Median (Min–Max)
Patient age (years) 32.0 (21.0–55.0) 27.0 (18.0–46.0) 0.101
BMI (kg/m2) 27.0 (19.0–38.0) 24.1 (15.0–37.7) 0.009
Fetuin-A (ng/ml) 303.3 (230.1–379.5) 387.4 (298.8–422.9) 0.0001
TSH (mIU/l) 18.9 (10.4–100.0) 1.3 (0.4–3.7) 0.0001
Systolic BP (mmHg) 110.0 (100.0–140.0) 110.0 (100.0–120.0) 0.106
Diastolic BP (mmHg) 70.0 (60.0–100.0) 60.0 (50.0–80.0) 0.012
Antithyroglobulin Ab (IU/ml) 82.4 (10.0–1246.0) 10.3 (10.0–120.7) 0.001
Antimicrosomal Ab (IU/ml) 310.4 (5.0–1525.0) 5.3 (2.8–29.0) 0.0001
Free T4 (mol/l) 8.2 (5.0–15.1) 14.5 (9.4–15.9) 0.001
Total cholesterol (mg/dl) 192.5 (112.0–320.0) 150.0 (112.0–218.0) 0.007
LDL (mg/dl) 113.0 (59.0–214.0) 90.0 (50.8–143.0) 0.025
HDL (mg/dl) 49.3 (23.0–83.9) 50.0 (30.0–70.7) 0.773
Triglyceride (mg/dl) 108.5 (41.0–761.0) 68.0 (34.0–123.0) 0.020
CRP (mg/l) 3.0 (2.6–41.8) 3.0 (0.4–14.0) 0.093
Fibrinogen (g/l) 3.2 (1.9–5.7) 2.5 (2.0–5.4) 0.063
FMD (%) 5.0 (2.3–10.5) 6.5 (2.0–10.2) 0.042
TSH, thyroid-stimulating hormone; BP, blood pressure; C, cholesterol; CRP, C-reactive protein; FMD, flow-mediated arterial
dilatation. Statistically significant P values are expressed as bold.
Table 2 Correlation between plasma fetuin-A levels and
baseline cardiovascular risk factors in patients with
hypothyroidism.
Baseline cardiovascular
risk factors r P
TSH K0.61 0.01
BMI 0.67 0.06
Systolic BP K0.134 0.488
Diastolic BP 0.073 0.707
Total C 0.156 0.436
LDL 0.166 0.407
HDL K0.092 0.648
Triglyceride 0.393 0.143
CRP 0.115 0.562
Fibrinogen 0.332 0.084
Flow-mediated arterial
dilatation
0.141 0.493
TSH, thyroid-stimulating hormone; BP, blood pressure; C, cholesterol;
CRP, C-reactive protein. Statistically significant P values are expressed
as bold.
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170 :3 414level was 362.5 (282.7–454.1) ng/ml following L-T4
treatment and was significantly higher than the baseline
values (PZ0.0001) in the patient group. There was no
significant difference between the plasma fetuin-A levels
after achievement of euthyroidism in the patient group
and the baseline plasma fetuin-A levels of the control
group (PZ0.388). In addition, baseline and 3-month
plasma fetuin-A levels of the control group were similar
(PZ0.286). There was no correlation between post-
treatment TSH levels and posttreatment plasma fetuin-A
levels (PZ0.054, rZK0.12).
Changes in cardiovascular risk factors following TSH
normalization are demonstrated in Table 3 in the study
group. BMI, diastolic blood pressure, total cholesterol, and
LDL-cholesterol levels were lower and flow-mediated
arterial dilatation was higher in the patient group at the
end of study period (Table 3). None of them were
correlated with plasma fetuin-A changes. Comparison of
posttreatment cardiovascular risk factors in patients and
baseline cardiovascular risk factors in controls are
presented in Table 4.
A regression analysis was carried out to determine the
impact of cardiovascular risk factors on plasma fetuin-A
levels independently fromhypothyroidism. The dependent
variable was plasma fetuin-A level. No significant
relationship was determined between fetuin-A levels and
any of the cardiovascular risk factors. However, hypo-
thyroidism and TSH levels were found to be the two
parameters affecting fetuin-A levels in all subjects (PZ0.024
and PZ0.021 respectively).www.eje-online.orgDiscussion
In this study, we found that hypothyroidism was
associated with lower plasma fetuin-A levels, independent
of other cardiovascular risk factors. Moreover, fetuin-A
levels in the patient group with L-T4 replacement were
returned to the normal levels as in controls. This is the first
study demonstrating the relation between low fetuin-A
levels and hypothyroidism, which are both cardiovascular
risk factors (5, 13).Downloaded from Bioscientifica.com at 12/26/2019 07:02:44AM
via free access
Table 3 Alteration in cardiovascular risk factors following treatment in patients with hypothyroidism.
Baseline Posttreatment
PMedian (Min–Max) Median (Min–Max)
BMI (kg/m2) 27.0 (19.0–38.0) 23 (15.5–34.0) 0.009
Total cholesterol (mg/dl) 192.5 (112.0–320.0) 180.0 (113.0–286.0) 0.005
LDL (mg/dl) 113.0 (59.0–214.0) 101.0 (66.8–207.0) 0.048
HDL (mg/dl) 49.3 (23.0–83.9) 44.0 (28.3–69.0) 0.052
Triglyceride (mg/dl) 108.5 (41.0–761.0) 104.0 (41.0–481.0) 0.954
Systolic BP (mmHg) 110.0 (100.0–140.0) 110.0 (100.0–145.0) 0.106
Diastolic BP (mmHg) 70.0 (60.0–100.0) 65.0 (60.0–85.0) 0.012
CRP (mg/l) 3.0 (2.6–41.8) 3.0 (3.0–51.4) 0.615
Fibrinogen (g/l) 3.2 (1.9–5.7) 2.8 (2.0–5.3) 0.298
FMD (%) 5.0 (2.3–10.5) 7.5 (3.0–15.2) 0.0001
BP, blood pressure; CRP, C-reactive protein; FMD, flow-mediated arterial dilatation. Statistically significant P values are expressed as bold.
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170 :3 415Fetuin-A is a glycoprotein synthesized mainly in the
liver. A major site of plasma protein production is the
hepatocyte, and various in vitro techniques have been used
to modulate the production of these essential proteins.
Gromakova et al. (28) have reported that thyroid status
affects the protein synthesis in liver by altering the
RNA polymerase activity, and that protein synthesis
is increased in hyperthyroidism and decreased in
hypothyroidism. Lin et al. (23) carried out an in vitro
experimental study and demonstrated that protein
synthesis is increased in direct interaction with the
promoter region of major proteins synthesized by the
liver including fetuin-A (a-2 hs glycoprotein) via the a-1
thyroid receptors with effects of T3. The results of these
studies may explain the low fetuin-A levels in patients
with hypothyroidism and its normalization via maintain-
ing euthyroidism. In a recent study investigating plasmaTable 4 Comparison of cardiovascular risk factors follo
controls.
Patients (measurements at mon
Median (Min–Max)
TSH (mIU/l) 2.2 (0.3–4.4)
BMI (kg/m2) 23.0 (15.5–34.0)
Total cholesterol (mg/dl) 180.0 (113.0–286.0)
LDL (mg/dl) 101.0 (66.8–207.0)
HDL (mg/dl) 44.0 (28.3–69.0)
Triglyceride (mg/dl) 104.0 (41.0–481.0)
Systolic BP (mmHg) 110.0 (100.0–145.0)
Diastolic BP (mmHg) 65.0 (60.0–85.0)
CRP (mg/l) 3.0 (3.0–51.4)
Fibrinogen (g/l) 2.8 (2.0–5.3)
FMD (%) 7.5 (3.0–15.2)
TSH, thyroid-stimulating hormone; BP, blood pressure; CRP, C
Statistically significant P values are expressed as bold.fetuin-A levels among thyroidectomized and radioactive
iodine-ablated patients, Gagnon et al. (29) reported
insignificant fetuin-A change with recombinant human
TSH. This finding supports that fetuin-A synthesis affected
thyroid hormone status more than serum TSH levels.
In another recent clinical study, Pamuk et al. (30)
demonstrated high fetuin-A levels in patients with
hyperthyroidism, which have returned to normal with
achieving euthyroidism. The latter study is also a suppor-
tive mirror image of our data. Lack of a clinical study
investigating plasma fetuin-A levels in patients with
hypothyroidism makes our study unique in medical
literature, and is also a limitation for making a comparison
with other human studies. However, the significant
negative correlation determined between plasma TSH and
fetuin-A levels in all subjects (PZ0.001, rZK0.79) was in
conformity with the in vitro experimental studies (23, 28).wing treatment in patients with hypothyroidism and
th 3) Control (measurements at baseline)
PMedian (Min–Max)
1.3 (0.4–3.7) 0.171
24.1 (15.0–35.7) 0.263
150.0 (112.0–218.0) 0.035
90.0 (50.8–143.0) 0.068
50.0 (30.0–70.7) 0.339
68.0 (34.0–123.0) 0.018
110.0 (100.0–120.0) 0.635
60.0 (50.0–80.0) 0.324
3.0 (0.4–14.0) 0.040
2.5 (2.0–5.4) 0.094
6.5 (2.0–10.2) 0.988
-reactive protein; FMD, flow-mediated arterial dilatation.
www.eje-online.org
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170 :3 416There is a strong association between coronary artery
calcification and cardiovascular events (20). Dystrophic
intimal calcification in atherosclerotic plaque allows
progression of atherosclerosis (31). Experimental studies
have demonstrated that calcium deposition in matrix
vesicles of vascular smooth muscle cells (VSMC) and
pericytes results in apoptosis and macrophage activation
with the help of release of inflammatory mediators
(32, 33). This in turn allows easier progression of the
atherosclerotic plaque and rupture with impairment of
biomechanical stability (34). A cell culture study carried
out with VSMC has demonstrated that fetuin-A decreases
intracellular vesicular calcium deposition and thus
prevents VSMC calcification and apoptosis (35). Increased
vascular calcification has been demonstrated in hypothyr-
oidism, whichmight result from decreased levels of matrix
gla protein, a systemic calcification inhibitor (21, 22).
However, the relationship between hypothyroidism and
fetuin-A, another systemic calcification inhibitor, has
been demonstrated in our study and might be yet another
cause of vascular calcification in hypothyroidism. Further
in vitro studies should be carried out to elucidate this issue.
Macrophages migrating into the lesion in the early
stage of atherosclerosis engulf oxidized LDL particles to
form foam cells and secrete chemokines. So the inflam-
matory process goes on and results in maturation of
atherosclerotic plaque (36). Oxidized LDL enters the
macrophage via scavenger receptors (37). CPPs syn-
thesized in the presence of fetuin-A has been suggested
to play a protective role against the inflammatory
component of atherosclerosis by decreasing oxidized-
LDL levels inside the macrophage through competition
in entering the cell, by binding the scavenger receptors on
macrophage surface in the atheroma plaque (3, 38). These
data suggest that demonstration of reduced fetuin-A levels
in patients with hypothyroidism might be deemed as the
establishment of a novel cardiovascular risk factor. Studies
have demonstrated a positive correlation between plasma
fetuin-A levels and other cardiovascular risk factors
including high arterial blood pressure, central obesity,
high triglyceride, and LDL-cholesterol levels, and impai-
red FMD indicating vascular resistance (39). Fetuin-A is
an endogenous inhibitor of the insulin receptor tyrosine
kinase and fetuin-A knockout mice exhibit an increased
insulin sensitivity (40, 41). Recent studies have proposed
association between high fetuin-A levels and cardiovas-
cular risk factors, such as increased risk of type 2 diabetes,
insulin resistance, hepatosteatosis, and metabolic syn-
drome (10, 42, 43). Although some of these cardiovascular
risk factors were present in our patient group, fetuin-Awww.eje-online.orglevel was found to be lower independent of those
mentioned earlier, suggesting a predominant effect of
hypothyroidism on fetuin-A levels. Improvement in some
cardiovascular risk factors, (i.e. serum lipids, BMI, blood
pressure, and FMD) was observed in our patient group at
the end of the study period, with maintained euthyroid-
ism. These changes did not correlate with plasma fetuin-A
changes, which suggested that hypothyroidism exerted an
independent effect on plasma fetuin-A levels. However,
the exact relationship between reduced fetuin-A levels and
increased cardiovascular risk in patients with hypothyr-
oidism cannot be determined due to the lack of a detailed
cardiovascular examination in the patient group and
follow-up of long-term cardiovascular events. We can
only make a projection with our results in conjunction
with the experimental and clinical data of previous studies.
Another major point to mention is whether our
methodology of fetuin-A measurement was valid for
patients with hypothyroidism. Although a recent study
has demonstrated that a sub-picogram-sensitive rapid
chemiluminescent immunoassay method is 125 times
more sensitive than the classical commercial ELISAmethod,
ELISA is still the gold standard and extensively usedmethod
inhuman fetuin-A screening (44). In our study,we also used
the commercially available ELISA method to measure
fetuin-A levels. Comparable mean fetuin-A level with that
of healthy controls of our study and of another study (45),
reduction in fetuin-A level to near-normal in patients with
hypothyroidism following treatment and lack of change
in fetuin-A levels of the control groupduring follow-upwere
supportive of the reliability of our study.
Consequently, reduced fetuin-A level, deemed as a
cardiovascular risk factor, was determined in our female
patients with hypothyroidism. Reduced fetuin-A level is
considered to aggravate cardiovascular events via vascular
calcification and inflammatory process in atherosclerosis
in these patients. Currently, it is not known whether
reduced plasma fetuin-A level is a marker of cardiovascular
risk in patients with hypothyroidism. However, further
experimental and observational studies might elucidate
this. Confirmation of the role of reduced fetuin-A level as a
cardiovascular risk marker may allow its use in initiating
treatment in special patient and disease groups including
cardiovascular disease concomitantly with hypothyroi-
dism, advanced age, or subclinical hypothyroidism.Declaration of interest
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